Holen Sie sich die Stockscreener-App
0.7154
2.31%
0.0127
Xilio Therapeutics Inc Aktie (XLO) Neueste Nachrichten
Xilio Therapeutics 2025 Q2 Earnings Improved EPS Amid Wider Net Loss - AInvest
Xilio Therapeutics Q2 Earnings Beat Expectations, Revenue Doubles to $8.084M. - AInvest
Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest
Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Xilio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xilio Therapeutics, Inc. SEC 10-Q Report - TradingView
Xilio Therapeutics Q2 2025 Financial Results and Business Updates - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire
Cancer Drug Breakthrough: Xilio's Vilastobart Delivers Strong Results with Fewer Side Effects - Stock Titan
Heatmap analysis for Xilio Therapeutics Inc. and competitorsTrade Plan With Low Risk High Return - Newser
Brokers Issue Forecasts for XLO Q2 Earnings - Defense World
Advanced analytics toolkit walkthrough for Xilio Therapeutics Inc.Free Stock Market Watch With Alerts - Newser
Analyzing drawdowns of Xilio Therapeutics Inc. with statistical toolsAsset Allocation Summary With Future Outlook - Newser
Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating, Sets Price Target of $2.00 - AInvest
How to use Fibonacci retracement on Xilio Therapeutics Inc.Momentum Entry Alerts with Risk Control - Newser
Using Bollinger Bands to evaluate Xilio Therapeutics Inc.Free High Conviction Intraday Stock Signals - Newser
Leerink Partners Maintains Xilio Therapeutics(XLO.US) With Buy Rating, Maintains Target Price $2 - 富途牛牛
Leerink Partners Begins Coverage on Xilio Therapeutics (NASDAQ:XLO) - Defense World
Xilio Therapeutics (XLO) Projected to Post Quarterly Earnings on Thursday - Defense World
Leerink Partners Initiates Coverage on Xilio Therapeutics with Outperform Rating - AInvest
Leerink Partners Initiates Xilio Therapeutics(XLO.US) With Buy Rating, Announces Target Price $2 - 富途牛牛
Xilio Therapeutics shares rise 4.95% premarket after Leerink Partners initiates coverage with an Outperform rating. - AInvest
Leerink Partners Initiates Xilio Therapeutics at Outperform With $2 Price Target - MarketScreener
Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating - Investing.com India
Leerink Partners initiates coverage on Xilio Therapeutics stock with Outperform rating By Investing.com - Investing.com South Africa
Xilio Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
When is Xilio Therapeutics Inc. stock expected to show significant growthCapitalize on market shifts before others do - Jammu Links News
What institutional investors are buying Xilio Therapeutics Inc. stockUnlock powerful investment tools for free - Jammu Links News
What makes Xilio Therapeutics Inc. stock price move sharplyAchieve consistent profits with smart trading - Jammu Links News
Is Xilio Therapeutics Inc. a growth stock or a value stockAchieve rapid wealth accumulation through smart investing - Jammu Links News
Why is Xilio Therapeutics Inc. stock attracting strong analyst attentionAccelerated wealth expansion - Jammu Links News
What are Xilio Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - Jammu Links News
What is Xilio Therapeutics Inc. company’s growth strategyIdentify winners with top-tier analysis - Jammu Links News
What are the latest earnings results for Xilio Therapeutics Inc.Maximize returns with effective portfolio management - Jammu Links News
Xilio Therapeutics Inc. Stock Analysis and ForecastNavigate the market with precision tools - Jammu Links News
MACD Cross Could Confirm Trend in Xilio Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What is the risk reward ratio of investing in Xilio Therapeutics Inc. stockMarket Forecast Data Feed From AI Tools - Jammu Links News
Xilio Therapeutics Awards $87K Worth of Stock Options in Key Employee Inducement Plan - Stock Titan
Why Xilio Therapeutics Inc. stock attracts strong analyst attentionVolume Based Entry Signal Outlook - beatles.ru
Certain Restricted Stock Units of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-AUG-2025. - MarketScreener
Will Xilio Therapeutics Inc. rebound enough to break evenRisk Adjusted Technical Entry Plan Gains Followers - metal.it
Breakout Traders Target Xilio Therapeutics Inc. on Recovery SetupCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Xilio Therapeutics Inc. Forms Bullish Flag — Upside AheadReal-Time Market Sentiment Tracking Gains Momentum - metal.it
Bristol Myers Squibb and Bain Capital Form New Immunology Company - MarketWatch
Does Xilio Therapeutics Inc. stock perform well during market downturnsTremendous growth opportunities - Jammu Links News
How does Xilio Therapeutics Inc. generate profit in a changing economyHigh-yield investments - Jammu Links News
Published on: 2025-07-28 02:43:54 - jammulinksnews.com
How Resilient Is Xilio Therapeutics Inc. Stock During Economic DownturnsMassive Upside Selection - Newser
What analysts say about Xilio Therapeutics Inc. stockHigh-yield capital appreciation - PrintWeekIndia
0.07%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):